Search

Standardization of Epidemiological Surveillance of Group A Streptococcal Impetigo

Impetigo is a highly contagious bacterial infection of the superficial layer of skin. Impetigo is caused by group A Streptococcus (Strep A) and Staphylococcus aureus, alone or in combination, with the former predominating in many tropical climates. Strep A impetigo occurs mainly in early childhood, and the burden varies worldwide. It is an acute, self-limited disease, but many children experience frequent recurrences that make it a chronic illness in some endemic settings.

Standardization of Epidemiological Surveillance of Group A Streptococcal Pharyngitis

Pharyngitis, more commonly known as sore throat, is caused by viral and/or bacterial infections. Group A Streptococcus (Strep A) is the most common bacterial cause of pharyngitis. Strep A pharyngitis is an acute, self-limiting disease but if undertreated can lead to suppurative complications, nonsuppurative poststreptococcal immune-mediated diseases, and toxigenic presentations.

Professor Jonathan Carapetis AM

Institute Director; Head, Strep A Translation; Co-Founder of REACH

Acute Rheumatic Fever Diagnosis Collaborative Network (ARC)

ARC is a global network of collaborators committed to reducing the burden of RHD in our lifetime.

Australian Strep A Vaccine Initiative (ASAVI)

The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.

BPG Formulation Preferences Study: Exploring patient, family and clinician reformulations preferences for BPG

The key objective of this study is to collect data about patient and clinician preferences about reformulations.

Burden of rheumatic heart disease (RHD) and impact of prevention strategies: comprehensive evidence to drive the RHD Endgame

This project will use a multi-jurisdictional linked RHD dataset to establish a baseline burden of RHD in Australia to allow for monitoring the impact of burden over time, and to form the basis of clearly defined targets for the END RHD CRE Endgame Strategy.

Defining target penicillin concentrations for subsequent studies of a reformulated long-acting benzathine penicillin prototype

Aims: To determine the minimum inhibitory concentrations of penicillin G against a representative collection of Strep A strains; and to evaluate the impact of penicillin G concentration and size of bacterial inoculum on the prophylactic effect for Strep A strains

Development of a longer acting formulation of Penicillin G for the treatment and prevention of acute rheumatic fever and rheumatic heart disease

This project aims to develop a longer acting formulation of penicillin, such that frequency of the injection can be increased up to 3-6 months.

Establishing a Western Australian Congenital and Acquired Heart Disease Database

The main objective of the study is to establish a comprehensive register of congenital and acquired heart disease in WA with accurate re-classification of all cases through Princess Margart Hospital using international diagnostic codes.